help button home button Endocrine Society Endocrine Reviews
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

First published online on September 4, 2007
Endocrine Reviews, doi:10.1210/er.2007-0003
A more recent version of this article appeared on October 1, 2007
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
28/6/664    most recent
Final Manuscript
Author Manuscript
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MM, K.
Right arrow Articles by A, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MM, K.
Right arrow Articles by A, I.

Neuropeptide Y Receptors Selective Ligands in the Treatment of Obesity

Kamiji MM and Inui A*

Department of Gastroenterology, Faculty of Medicine, University of Sao Paulo, Ribeirão Preto Campus, Ribeirão Preto, Brazil ; Department of Behavioral Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan

* To whom correspondence should be addressed. E-mail: inui{at}m.kufm.kagoshima-u.ac.jp.

Obesity is a serious public health problem throughout the world, affecting both developed societies and developing countries. The central nervous system has developed a meticulously interconnected circuitry in order to keep us fed and in adequate nutritional state. One of these consequences is that an energy dense environment favors the development of obesity NPY is one of the most abundant and widely distributed peptides in the central nervous system (CNS) of both rodents and humans and has been implicated in a variety of physiological actions. Within the hypothalamus, NPY play an essential role in the control of food intake and body weight. Centrally administered NPY causes robust increases in food intake and body weight and, with chronic administration, can eventually produce obesity. NPY activates a population of at least six G protein-coupled Y receptors. NPY analogues exhibit varying degrees of affinity and specificity for these Y receptors. There has been renewed speculation that ligands for Y receptors may be of benefit for the treatment of obesity. This review highlights the therapeutic potential of Y1, Y2, Y4 and Y5 receptors agonists and antagonists as additional intervention to treat human obesity.


Key words: Appetite Regulation • Body Weight • Food Intake • Neuropeptide Y • Neuropeptide Y Receptors • Obesity




This article has been cited by other articles:


Home page
DiabetesHome page
A. M. van den Hoek, C. van Heijningen, J. P. Schroder-van der Elst, D. M. Ouwens, L. M. Havekes, J. A. Romijn, A. Kalsbeek, and H. Pijl
Intracerebroventricular Administration of Neuropeptide Y Induces Hepatic Insulin Resistance via Sympathetic Innervation
Diabetes, September 1, 2008; 57(9): 2304 - 2310.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society